Supernus Pharmaceuticals, Inc. (SUPN) insider trading.
In Q3 2026, insiders at Supernus Pharmaceuticals, Inc. reported 10 non-derivative transactions on 10 Forms 3, 4 and 5: 0 open-market purchases and 0 sales.
- Transactions
- 10
- Purchases (P)
- 0
- Sales (S)
- 0
- Net shares, P minus S
- 0
- Insiders
- 5
- Last filed
- 2026-08-14
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Dec Timothy C | Officer · Senior Vice-President & CFO | 2 | 0 | 0 |
| Bhatt Padmanabh P. | Officer · Sr. VP of IP, CSO | 2 | 0 | 0 |
| Khattar Jack A. | Director, Officer · President, CEO | 2 | 0 | 0 |
| Mottola Frank | Officer · SVP, Chief Tech. Ops. Officer | 2 | 0 | 0 |
| Rubin Jonathan | Officer · SVP, Chief Medical Officer | 2 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-12 | Dec Timothy C | M (A) | 1,250 | $0 | 9,733 | Form 4 |
| 2026-08-12 | Dec Timothy C | F (D) | 604 | $46.57 | 9,129 | Form 4 |
| 2026-08-12 | Bhatt Padmanabh P. | F (D) | 1,158 | $46.57 | 18,637 | Form 4 |
| 2026-08-12 | Bhatt Padmanabh P. | M (A) | 2,500 | $0 | 19,795 | Form 4 |
| 2026-08-12 | Khattar Jack A. | M (A) | 29,849 | $0 | 1,270,993 | Form 4 |
| 2026-08-12 | Khattar Jack A. | F (D) | 12,642 | $46.57 | 1,258,351 | Form 4 |
| 2026-08-12 | Mottola Frank | M (A) | 1,650 | $0 | 20,341 | Form 4 |
| 2026-08-12 | Mottola Frank | F (D) | 797 | $46.57 | 19,544 | Form 4 |
| 2026-08-12 | Rubin Jonathan | F (D) | 363 | $46.57 | 13,979 | Form 4 |
| 2026-08-12 | Rubin Jonathan | M (A) | 750 | $0 | 14,342 | Form 4 |
Transaction codes in this quarter
Get SUPN insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1356576&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · SUPN company page · Supernus Pharmaceuticals, Inc. on SEC.gov
Questions
Are insiders buying or selling Supernus Pharmaceuticals, Inc. (SUPN)?
In Q3 2026, insiders at Supernus Pharmaceuticals, Inc. reported 10 non-derivative transactions on 10 Forms 3, 4 and 5: 0 open-market purchases and 0 sales. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Supernus Pharmaceuticals, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/supn.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.